Cardima Inc. (fka CADMQ)

[di4]

Cardima Surgical Ablation System Featured in Podium Presentation by Dr. Li Poa at ACTS 2009 Meeting
Company to Exhibit Surgical Ablation System Products at ACTS 2009 and American Association of Thoracic Surgeons Meetings
May 6, 2009 4:00:00 AM
Copyright Business Wire 2009


Email Story Discuss on ZenoBank

View Additional ProfilesFREMONT, Calif.--(BUSINESS WIRE)-- Cardima, Inc. (OTCBB: CADM) today announced that surgical ablation thought leader, Dr. Li Poa, will present data from his experience with the Cardima Surgical Ablation System at the ACTS 2009: Advanced Cardiac Techniques in Surgery Meeting on May 7, 2009. Cardima also will showcase its products and technologies at the ACTS 2009 meeting being held on May 6-7, 2009 in New York, as well as at the 89th Annual Meeting of the American Association for Thoracic Surgery (AATS) May 9-13, 2009 in Boston. Cardima executives will attend both conferences to meet with industry executives and interested investors.

Dr. Poa, FACS, Chief of Cardiothoracic Surgery and Cardiac Surgery Program Director at Stamford Hospital, Connecticut, and faculty member of Columbia University, New York, heads the Cardima Center of Excellence and Training Program at Stamford Hospital. "I look forward to presenting data collected from procedures using the Cardima Surgical Ablation System in my presentation, 'Keys to Surgical Ablation: Stamford Experience with the Cardima System,'" Dr. Poa said. "The Cardima system is capable of creating a fairly complete, complex lesion set during both open- and closed-chest procedures. It can reliably and reproducibly establish both entrance and exit conduction block, which is an important attribute for achieving effective, long-term ablation results. Additionally, the system is capable of creating continuous transmural lesions without gaps, and can be easily manipulated to create all the necessary lesions for a full surgical procedure."

"We are delighted that Dr. Poa, a recognized world-leading authority on surgical ablation, will share his experience with the Cardima Surgical Ablation System at this international gathering of cardiothoracic surgeons and thought-leaders," said Cardima's CEO, Robert Cheney. "Creating awareness about the advanced features of our Surgical Ablation System at key meetings such as the ACTS 2009 and AATS, along with developing Centers for Excellence and broadening distribution are integral parts of our strategy to support product adoption."

Cardima Product Exhibition Information:

-- At the ACTS 2009 meeting, May 6-7, Cardima products and technology will
be displayed at the Exhibit Hall at the Equitable Center. The ACTS 2009
meeting features the latest surgical and interventional therapies for
heart valve and coronary artery diseases, chronic atrial fibrillation
and diseases of the aorta.
-- At AATS, May 9-13, Cardima products will be showcased at the Hynes
Convention Center at exhibition booth #608. The AATS annual meeting
brings together the world's leading scientists in thoracic and
cardiovascular surgery to discuss their latest clinical and research
efforts.

For physicians attending ACTS 2009 or AATS interested in learning more about Cardima's Surgical Ablation Program, please contact Anita Elliot via email at [e-mail].

About Cardima Surgical Ablation System

The Surgical Ablation System uses Cardima's patented technology for the ablation of cardiac tissue. The System incorporates a microcatheter-based surgical probe coupled with Cardima's INTELLITEMP(R), a radiofrequency energy management device. The probe incorporates irrigation, suction and illumination, which aid in placement and lesion depth. The Cardima Surgical Ablation System is able to create deep, long, linear and transmural cardiac lesions without gaps. The small, flexible design offers sole port-hole access, potentially decreasing procedure time, patient hospital stay and discomfort.

About Cardima

Cardima, Inc. has developed the PATHFINDER(R), TRACER(TM) and REVELATION(R) Series of diagnostic catheters, the VUEPORT(R) and NAVIPORT(R) Series of guiding catheters, the INTELLITEMP(R) Energy Management Device and the Surgical Ablation System. All of these Cardima devices have received CE mark approval and U.S. Food and Drug Administration (FDA) 510(k) clearance. The REVELATION(R) Series of ablation catheters with the INTELLITEMP(R) EP Energy Management Device, developed for the treatment of atrial fibrillation (AF), has received CE mark approval and is marketed in Europe.

PATHFINDER(R), TRACER(TM), VUEPORT(R), NAVIPORT(R), REVELATION(R) and INTELLITEMP(R) are registered trademarks of Cardima, Inc.

Forward-Looking Statements

This press release may contain forward-looking statements. These statements are subject to risks and uncertainties. Investors are referred to the full discussion of risks and uncertainties associated with forward-looking statements as contained in our reports to the Securities and Exchange Commission, including our Forms 10-K and 10-Q. The Company assumes no obligation to update the forward-looking information.




Source: Cardima, Inc.


----------------------------------------------
Company Contact
Cardima
Inc.
Richard Gaston MD
510-354-0300
http://www.Cardima.com
or
Investor Contacts
Lippert/Heilshorn & Associates
Jody Cain or Kevin Mc Cabe
310-691-7100
[e-mail]
[e-mail]